ArticleHuman vaccines & immunotherapeutics2024
A bibliometric analysis from 2014 to 2024 reveals research hotspots and trends in the immunotherapy for glomerulonephritis.
Article in Human vaccines & immunotherapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Based on bibliometric visual analysis, the current status and development trends of research on complications after cholecystectomy.Frontiers in surgery · 2025Pooled it
- Mechanism-centered target discovery across glomerulonephritis phenotypes: an integrative multi-omics study.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Article
- A bibliometric analysis on immunotherapy treatments for systemic lupus erythematosus: analysis of published evidence from 2014 to 2024.Clinical rheumatology · 2026Article
- A practical guide for nephrologist peer reviewers: understanding and appraising Mendelian randomization studies.Renal failure · 2025Article
- Research hotspots and trends in lung cancer immunotherapy are revealed by a bibliometric study spanning the years 2004 to 2024.Human vaccines & immunotherapeutics · 2025Article
- Bibliometric analysis of global research hotspots in ovarian cancer immunotherapy from 2014 to 2024 using CiteSpace.Human vaccines & immunotherapeutics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to present an overview of the current status of research and important discoveries about immunotherapy for glomerulonephritis in general using bibliometric analysis. We collected the literature on immunotherapy for glomerulonephritis from the Web of Science (WOS) database for the last 10 years (2014-2024), and we assessed the mapping of knowledge using Citespace. The findings demonstrated that there were 258 articles concerning the immunotherapy for glomerulonephritis, with a faster growth after 2018. The USA, Charite Universitatsmedizin Berlin, and Anders, Hans-Joachim are the nation, organization, and writer with the highest number of publications. The most often cited reference is Rovin BH (2021) as well (5). The best partnerships are formed by prestigious universities and developed countries for glomerulonephritis research on immunotherapy. Three research hotspots in this area are rituximab, adjuvant, and antibody production erythematosus, respectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.